Literature DB >> 15662488

Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature.

Aaron M Milstone1, Kevin Meyers, Josephine Elia.   

Abstract

Neuropsychiatric lupus can be difficult to diagnose, and little prospective data exists to help direct management. In this case report we describe the acute onset of symptoms of depression, mania, and psychosis and their complete resolution 48 h following a 5-day treatment course of intravenous immunoglobulin (IVIG) in a 20-year-old woman with systemic lupus erythematosus (SLE). We review the literature on IVIG for the management of neuropsychiatric lupus. We propose that when more toxic therapies are refused or symptoms do not remit with other treatments, IVIG should be considered in patients with neuropsychiatric lupus.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15662488     DOI： 10.1007/s10067-004-1046-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  21 in total

1.  Successful treatment of early secondary myelofibrosis in SLE with IVIG.

Authors:  A Aharon; Y Levy; Y Bar-Dayan; A Afek; G Zandman-Goddard; Y Skurnik; F Fabrrizzi; Y Shoenfeld
Journal:  Lupus       Date:  1997       Impact factor: 2.911

2.  Plasma exchange for cerebral lupus erythematosus.

Authors:  B Unterweger; G Klein; W W Fleischhacker
Journal:  Biol Psychiatry       Date:  1988-12       Impact factor: 13.382

Review 3.  The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.

Authors: 
Journal:  Arthritis Rheum       Date:  1999-04

4.  Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin.

Authors:  Y Sherer; Y Levy; P Langevitz; M Lorber; F Fabrizzi; Y Shoenfeld
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

5.  Risk factors for central nervous system involvement in systemic lupus erythematosus.

Authors:  F B Karassa; J P Ioannidis; G Touloumi; K A Boki; H M Moutsopoulos
Journal:  QJM       Date:  2000-03

6.  Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.

Authors:  R L Brey; S L Holliday; A R Saklad; M G Navarrete; D Hermosillo-Romo; C L Stallworth; C R Valdez; A Escalante; I del Rincón; G Gronseth; C B Rhine; P Padilla; D McGlasson
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

7.  The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus.

Authors:  C Michael Neuwelt
Journal:  Ther Apher Dial       Date:  2003-04       Impact factor: 1.762

8.  Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus.

Authors:  E Toubi; M A Khamashta; A Panarra; G R Hughes
Journal:  Am J Med       Date:  1995-10       Impact factor: 4.965

Review 9.  MRI and the brain in systemic lupus erythematosus.

Authors:  J W Graham; W Jan
Journal:  Lupus       Date:  2003       Impact factor: 2.911

10.  Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis.

Authors:  J Press; K Palayew; R M Laxer; K Elkon; A Eddy; D Rakoff; E D Silverman
Journal:  Arthritis Rheum       Date:  1996-04
View more
  16 in total

Review 1.  Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

Review 2.  [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

Review 3.  Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Authors:  Gisele Zandman-Goddard; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  Current and novel therapeutics in the treatment of systemic lupus erythematosus.

Authors:  Cagri Yildirim-Toruner; Betty Diamond
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

Review 5.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 6.  Reviewing the recommendations for lupus in children.

Authors:  Zehra Serap Arıcı; Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

7.  Psychosis in a young female - a diagnostic and therapeutic challenge.

Authors:  Sharmin Nizam; Andrew Gough
Journal:  JRSM Short Rep       Date:  2010-08-31

Review 8.  Pragmatic approaches to therapy for systemic lupus erythematosus.

Authors:  Wen Xiong; Robert G Lahita
Journal:  Nat Rev Rheumatol       Date:  2013-10-29       Impact factor: 20.543

Review 9.  The diverse and complex modes of action of anti-NMDA receptor autoantibodies.

Authors:  Lonnie P Wollmuth; Kelvin Chan; Laurent Groc
Journal:  Neuropharmacology       Date:  2021-05-31       Impact factor: 5.250

Review 10.  Lupus acute cardiomyopathy is highly responsive to intravenous immunoglobulin treatment: Case series and literature review.

Authors:  Katya Meridor; Yehuda Shoenfeld; Oshrat Tayer-Shifman; Yair Levy
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.